- Home
- UPXI vs SERA Comparison
UPXI vs SERA Comparison
Compare UPXI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | SERA |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.3M | 75.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UPXI | SERA |
|---|---|---|
| Price | $0.90 | $1.93 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 57.2K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.49 | 32.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,811,345.00 | $81,000.00 |
| Revenue This Year | $118.99 | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.54 | $1.56 |
| 52 Week High | $12.35 | $4.09 |
Technical Indicators
Market Signals| Indicator | UPXI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 31.18 | 45.37 |
| Support Level | $0.54 | $1.91 |
| Resistance Level | $1.17 | $2.03 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 9.36 | 37.43 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.